Invention Grant
- Patent Title: N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
-
Application No.: US15896378Application Date: 2018-02-14
-
Publication No.: US10392350B2Publication Date: 2019-08-27
- Inventor: Thomas D. Aicher , Donald J. Skalitzky , Clarke B. Taylor
- Applicant: Lycera Corporation
- Applicant Address: US MI Ann Arbor
- Assignee: Lycera Corporation
- Current Assignee: Lycera Corporation
- Current Assignee Address: US MI Ann Arbor
- Agency: Dechert LLP
- Main IPC: C07D231/38
- IPC: C07D231/38 ; C07D405/04 ; C07D401/08 ; C07D403/04 ; C07D405/08 ; C07D401/04
Abstract:
The invention provides pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
Public/Granted literature
- US20180222867A1 N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF Public/Granted day:2018-08-09
Information query
